



**Biocon Limited**

20th KM Hosur Road  
Electronics City  
Bangalore 560 100, India  
T 91 80 2808 2808  
F 91 80 2852 3423  
CIN : L24234KA1978PLC003417

Date of submission: June 23, 2018

[www.biocon.com](http://www.biocon.com)

To The Secretary Listing Department BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code - 532523	To The Secretary Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Code- BIOCON
---	---

Dear Sir/Madam,

**Sub:** Biocon's Sterile Drug Product facility receives Establishment Inspection Report (EIR) from USFDA

**Ref:** Regulations 30 of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.

Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, please find below the "Company Statement" on the subject matter.

*"The Company confirms that Biocon has received an Establishment Inspection Report (EIR) from the USFDA for its Sterile Drug Product manufacturing facility in Bangalore, following the USFDA pre-approval inspection of this facility in April/ May 2018. EIR notifies that the inspection stands closed. Biocon is committed to global standards of quality and compliance."* Company Spokesperson

We request you to kindly take this to your records as per the requirement of LODR and oblige.

Thanking You,  
Yours faithfully  
For Biocon Limited

Akhilesh Nand  
Chief Compliance Officer